News

CMN Weekly (4 November 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Nov. 4, 2022

Top picks

Research

Industry

Detection

Reviews

  • Chinese researchers summarise the limitation of current CRISPR-based diagnostics. Then, they elaborate in detail on how five different types of microfluidics improve the performance of current CRISPR-based assays. In addition, they overlook the future development of CRISPR-based microfluidic assays and their applications.

Financial reports have been reported by

Upcoming presentations for ASH 2022 (American Society of Hematology)

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (4 November 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid Tumors (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine